Assessing the Risks and Benefits of BCG Vaccination in Infants with SCID
Author Information
Author(s): Clark Michael, Cameron D William
Primary Institution: University of Ottawa
Hypothesis
What are the threshold values for SCID incidence above which BCG vaccination poses greater risks than benefits?
Conclusion
BCG vaccination may not be safe for Canadian Aboriginal children at high risk for SCID, suggesting the need for alternative TB control measures.
Supporting Evidence
- BCG vaccination is effective against severe forms of TB but poses risks for infants with SCID.
- The threshold for SCID incidence above which BCG is not supported is 4.2 per 100,000 births.
- BCG is associated with a significant increase in QALYs if the ARI is 1% and SCID incidence is below 5 per 100,000.
- Secondary effects of BCG vaccination due to reduced transmission were not included in the model.
Takeaway
This study looks at whether giving a vaccine to babies with a serious immune problem is safe, and it finds that it might not be.
Methodology
A Markov model was developed to simulate the natural histories of tuberculosis and SCID in children from birth to 14 years.
Potential Biases
The model's conclusions are based on assumptions made in formulating the model.
Limitations
The model did not include secondary effects of BCG vaccination due to reduced transmission and focused only on a theoretical cohort from birth to age 14 years.
Participant Demographics
Participants included medical students, health employees, and community staff, with a mean utility value for neurological sequelae assessed.
Statistical Information
P-Value
0.36
Confidence Interval
95% CI 0.37, 0.49
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website